Holding off on at best neutral outcomes. Vytorin/Zetia will be thrown into Diabetes bag. Liptruzet gone! Get out while you can!
Anacetrapib is just around the corner, don't you know. This is going to be another great drug from Merck even though everybody else's has failed. The individuals that championed this drug are long gone now so this failure doesn't taint them.
Merck pays $1B to buy into Bayer's cardio future May 6, 2014 | By Damian Garde SHARE TOOLS Comment Print Contact Author Reprint Merck ($MRK) plans to use the proceeds of its planned $14.2 billion consumer business sale to Bayer to beef up its pipeline, and the in-transition pharma giant isn't wasting any time, signing a billion-dollar deal with its new partner in a move to get its hands on some new cardiovascular drugs. Under the agreement, Merck will hand over $1 billion up front to split the rights to Bayer's stable of drugs that modulate soluble guanylate cyclase (sGC), an enzyme tied to the widening of blood vessels. That includes ex-U.S. rights to Adempas, Bayer's FDA-approved treatment for pulmonary arterial hypertension, and stateside rights to vericiguat, a Phase II sGC modulator under development for worsening heart failure. Merck is on the line for another $1.1 billion in milestone payments tied to collective sales of the whole franchise, Bayer said. Merck also gets opt-in rights on the rest of Bayer's early-stage sGC drugs and has agreed to make its similar candidates available under the same terms. The two plan to share costs and profits on all co-developed treatments along the way. Read more: Merck pays $1B to buy into Bayer's cardio future - FierceBiotech http://www.fiercebiotech.com/story/merck-pays-1b-buy-bayers-cardio-future/2014-05-06#ixzz31Xq8cRoQ Subscribe at FierceBiotech
